Shares of Kura Oncology Inc (NASDAQ:KURA) have been given a consensus rating of “Buy” by the eleven analysts that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, nine have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $28.83.
Several equities analysts recently commented on the company. ValuEngine upgraded United Overseas Bank from a “sell” rating to a “hold” rating in a research report on Monday, June 17th. Leerink Swann set a $27.00 target price on Kura Oncology and gave the stock a “buy” rating in a research report on Saturday, June 15th. Citigroup set a $27.00 target price on PhaseBio Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, May 24th. Oppenheimer set a $13.00 target price on Alpine Immune Sciences and gave the stock a “buy” rating in a research report on Tuesday, March 19th. Finally, Zacks Investment Research downgraded ExlService from a “hold” rating to a “sell” rating in a research report on Wednesday, July 10th.
In related news, insider Antonio Gualberto sold 18,000 shares of the firm’s stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $21.11, for a total transaction of $379,980.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 15.30% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in KURA. Great Point Partners LLC increased its holdings in Kura Oncology by 30.7% during the 4th quarter. Great Point Partners LLC now owns 2,769,527 shares of the company’s stock valued at $38,884,000 after purchasing an additional 650,421 shares in the last quarter. Dimensional Fund Advisors LP acquired a new stake in Kura Oncology during the 4th quarter valued at $2,222,000. California Public Employees Retirement System increased its holdings in Kura Oncology by 228.6% during the 4th quarter. California Public Employees Retirement System now owns 153,300 shares of the company’s stock valued at $2,152,000 after purchasing an additional 106,641 shares in the last quarter. Fosun International Ltd increased its holdings in Kura Oncology by 49.8% during the 1st quarter. Fosun International Ltd now owns 305,958 shares of the company’s stock valued at $4,972,000 after purchasing an additional 101,724 shares in the last quarter. Finally, Spark Investment Management LLC acquired a new stake in Kura Oncology during the 1st quarter valued at $1,073,000. 83.89% of the stock is owned by hedge funds and other institutional investors.
Shares of Kura Oncology stock traded up $0.18 during midday trading on Monday, hitting $20.33. 474,912 shares of the company were exchanged, compared to its average volume of 258,729. The company has a debt-to-equity ratio of 0.05, a quick ratio of 13.80 and a current ratio of 13.80. The company has a market capitalization of $769.53 million, a price-to-earnings ratio of -11.82 and a beta of 2.51. Kura Oncology has a 52 week low of $10.20 and a 52 week high of $22.00. The firm has a 50 day simple moving average of $18.43.
Kura Oncology (NASDAQ:KURA) last posted its earnings results on Tuesday, May 7th. The company reported ($0.37) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.45) by $0.08. As a group, sell-side analysts anticipate that Kura Oncology will post -1.71 earnings per share for the current year.
About Kura Oncology
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Recommended Story: What is intrinsic value?
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.